![Alexey Vinogradov](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Alexey Vinogradov
Direttore/Membro del Consiglio presso XENETIC BIOSCIENCES, INC.
Patrimonio netto: 72 848 $ in data 31/05/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Alexey Shafranov | M | 45 | 19 anni | |
Carmine Stengone | M | 48 |
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | 12 anni |
Petr Vladimirovich Kruglyakov | M | 46 | 11 anni | |
Dmitriy Genkin | M | 56 | 19 anni | |
Jay Lichter | M | 62 |
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
Grigory Borisenko | M | 55 | 5 anni | |
James Callaway | M | 68 | 7 anni | |
Artem Vladimirovich Orlov | M | 48 | 11 anni | |
Roman Sergeevich Knyazev | M | 44 | 11 anni | |
Sergey Avtushenko | M | 56 | 17 anni | |
James Parslow | M | 59 | 7 anni | |
Roger Kornberg | M | 76 | 8 anni | |
Dmitry Yuryevich Kolosov | M | 44 | 11 anni | |
Adam Logal | M | 46 | 7 anni | |
Firdaus Jal Dastoor | M | 72 | 10 anni | |
Timothy Scott | M | - |
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
Robin Stevenson | M | - |
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | 3 anni |
Efim Prilezhaev | M | - | 1 anni | |
Nina Podkolzina | F | 50 | 1 anni | |
Stefan Heller | M | 58 |
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
Robin Stevens | M | 71 |
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
Moshe Mizrahy | M | 71 | - | |
Sergey Kimovich Bezhanov | M | 65 | - | |
Susan P. Stimson | F | 51 |
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | 5 anni |
Vladimir Olegovich Kutyrov | M | 57 | - | |
Yuliya Yurievna Yakovleva | F | 53 | - | |
Pavel Rodyukov | M | - | 1 anni | |
Steve Gorelik | M | 45 | 17 anni | |
Roza Vasilyevna Mikhaylova | F | - | - | |
Dmitriy Nikolayevich Poznyak | M | - | - | |
Indrek Kasela | M | 52 | 17 anni | |
Alexandra Vladimirovna Tuchkova | F | - | - | |
Olga Yuryevna Shpichko | M | 49 | 11 anni | |
Jesus E. Gonzalez | M | - |
Avelas Biosciences, Inc.
![]() Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | - |
Ivan Ozhgikhin | M | - | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Jeffrey Eisenberg | M | 58 | 8 anni | |
David Gryska | M | 68 | 2 anni | |
Brian Underdown | M | 83 | 17 anni | |
Jean Lamarre | M | 70 | 2 anni | |
Curtis Lockshin | M | 64 | 10 anni | |
Philippe van Holle | M | 69 | 2 anni | |
John D. Menditto | M | - | 2 anni | |
Lee F. Allen | M | 72 | 1 anni | |
Frederick M. Miesowicz | M | 75 | 13 anni | |
Olga Bioprocess Golub | F | - |
Bioprocess Capital Partners Ltd.
![]() Bioprocess Capital Partners Ltd. Investment ManagersFinance Bioprocess Capital Partners Ltd (BCP) is a venture capital firm founded in 2006. The firm is headquartered in Moscow, Russia. | 1 anni |
Igor Krol | M | 51 | - | |
Joan C. Winterbottom | F | 67 | 2 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 28 | 59.57% |
Russia | 21 | 44.68% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Alexey Vinogradov
- Contatti personali